Dec 20, 2025 • PR Newswire
BEARISH
Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
The Gross Law Firm is urging shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) who incurred losses during the class period of March 10, 2024, to September 29, 2025, to join a class action lawsuit. The complaint alleges that the company made false or misleading statements regarding its sole drug candidate, SLK, particularly its purported superiority over BIMZELX. Shareholders have until December 15, 2025, to register as lead plaintiff.
Dec 18, 2025 • ABC27
BEARISH
MLTX SHAREHOLDER NEWS: Did MoonLake Immunotherapeutics Mislead Investors? Contact BFA Law about the Ongoing Securities Class Action by December 15 Deadline
Bleichmar Fonti & Auld LLP has filed a securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) and its executives. The lawsuit alleges that MoonLake misled investors regarding the efficacy of its drug sonelokimab, leading to a significant stock price drop after disappointing Phase 3 trial results. Investors who purchased MoonLake common stock have until December 15, 2025, to seek appointment as lead plaintiff in the case.
Dec 17, 2025 • WLNS 6 News
BEARISH
Lost Money on MoonLake Immunotherapeutics (MLTX)? Join Class Action Before December 15, 2025 - Contact Levi & Korsinsky
A class action lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ:MLTX) based on alleged securities fraud between March 10, 2024, and September 29, 2025. Shareholders who suffered losses due to purportedly false statements concerning the company's sole drug candidate, SLK, and its clinical benefits compared to BIMZELX, are encouraged to join the class action before December 15, 2025. Levi & Korsinsky, LLP is representing the aggrieved shareholders.
Dec 16, 2025 • ABC4 Utah
BEARISH
Join Class Action to Recover Losses from MoonLake Immunotherapeutics (MLTX) - Contact Levi & Korsinsky Before December 15, 2025
Levi & Korsinsky, LLP has filed a securities class action lawsuit against MoonLake Immunotherapeutics (MLTX) on behalf of investors who suffered losses between March 10, 2024, and September 29, 2025. The lawsuit alleges that MoonLake made false statements and concealed information regarding its drug candidate, SLK, specifically concerning its purported superiority over BIMZELX. Investors affected are encouraged to contact Levi & Korsinsky to explore potential recovery under federal securities laws before December 15, 2025.
Dec 16, 2025 • CBS 42
BEARISH
Lost Money on MoonLake Immunotherapeutics (MLTX)? Join Class Action Before December 15, 2025 - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a class action securities lawsuit against MoonLake Immunotherapeutics (NASDAQ:MLTX) on behalf of investors who suffered losses between March 10, 2024, and September 29, 2025. The lawsuit alleges that the company made false statements regarding its drug candidate, SLK, and its purported superiority to monoclonal antibodies. Shareholders affected are encouraged to contact Levi & Korsinsky for information on potential recovery.
Dec 16, 2025 • CBS 42
BEARISH
Portnoy Law Firm Announces Class Action on Behalf of Moonlake Immunotherapeutics, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX). The lawsuit alleges that MoonLake made misleading statements regarding its sole drug candidate, sonelokimab (SLK), developed for hidradenitis suppurativa (HS), particularly concerning its efficacy compared to a competing drug. Investors who purchased securities between March 10, 2024, and September 29, 2025, have until December 15, 2025, to file a lead plaintiff motion.